Home Page

deltaDOT develops and commercialises innovative technologies for the separation and analysis of biomolecules. deltaDOT's core technology Label Free Intrinsic Imaging (LFII™), allows the direct monitoring of unlabelled biomolecules. This results in faster, higher quality results at a fraction of the cost of conventional approaches.

News

In May of this year deltaDOT Ltd. of London has received new investment as a part of the Company's financial and management restructuring. In addition to the new capital received from deltaDOT existing investors, a major manufacturing subcontractor decided to join in this investment round. The Company is now poised for a significant drive in the market exploitation of their unique technology. In addition to previous sales and applications of the Peregrine machines, this year a number of major international players and government organizations have successfully evaluated deltaDOT LFII technology for their specific applications. At this time our continuing contractual discussions with several of these customers are in final stages and orders are expected imminently.
 
Apart from the sales of Peregrine LFII machines, deltaDOT is actively seeking and is in discussions with major players in Life Sciences industry to license its patented technology for OEM labeled products.
 
While acknowledging that the recent difficult economic situation has subdued the capital equipment market, the Company's board of directors has confidence in the market success of deltaDOT unique technology.